Research
Hormonal
GLP-1 receptor agonists (specifically semaglutide and tirzepatide) offer superior glycemic control and significant weight loss compared to other antidiabetic drugs, with tirzepatide showing potential for diabetes remission.
For type 2 diabetes, especially if you are overweight, GLP-1 agonists like semaglutide and tirzepatide are highly effective. Tirzepatide, in particular, has shown the ability to put diabetes into remission for many patients, along with significant weight loss.
StrongSupportsVERY_HIGH confidence
Tirzepatide is a synthetic peptide consisting of 39 amino acids, a dual GIP/GLP-1 receptor agonist. In the SURPASS-1 study... the proportion of patients who reached 'diabetes remission' levels with HbA1c below 5.7% and showed normal blood glucose was approximately 50% in the tirzepatide 15 mg group.
Why this rating
Based on multiple Phase 3 trials (PIONEER, STEP, SURPASS) cited.
Source
Characteristics of the Latest Therapeutic Agent for Diabetes
Nuri Yun · Journal of Korean Diabetes · 2023
DOI 10.4093/jkd.2023.24.3.148
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors (specifically enavogliflozin and sotagliflozin) provide superior glycemic control and cardiovascular/renal benefits compared to placebo or standard care in patients with type 2 diabetes, with sotagliflozin specifically indicated for heart failure.Good
- Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces the risk of heart failure and kidney disease progression in patients with chronic kidney disease and type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →